• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Safety and Efficacy of Biologic Medications and Janus Kinase Inhibitors in Patients with Down Syndrome: A Retrospective Cohort Study.

作者信息

Westerkam Linnea, Pearson Lauren, Sayed Christopher

机构信息

University of North Carolina School of Medicine, Chapel Hill, NC, USA.

Department of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

出版信息

Clin Drug Investig. 2024 Mar;44(3):219-222. doi: 10.1007/s40261-024-01348-0. Epub 2024 Feb 19.

DOI:10.1007/s40261-024-01348-0
PMID:38372935
Abstract
摘要

相似文献

1
Safety and Efficacy of Biologic Medications and Janus Kinase Inhibitors in Patients with Down Syndrome: A Retrospective Cohort Study.生物药物和Janus激酶抑制剂在唐氏综合征患者中的安全性和有效性：一项回顾性队列研究
Clin Drug Investig. 2024 Mar;44(3):219-222. doi: 10.1007/s40261-024-01348-0. Epub 2024 Feb 19.
2
Biological and JAK inhibitor therapy outcomes for severe psoriasis in trisomy 21.21 三体综合征重度银屑病的生物制剂和 JAK 抑制剂治疗结果。
J Dermatol. 2023 Oct;50(10):1339-1342. doi: 10.1111/1346-8138.16851. Epub 2023 Jun 8.
3
Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study.JAK激酶抑制剂乌帕替尼治疗化脓性汗腺炎的真实世界安全性及临床反应：一项回顾性队列研究
J Am Acad Dermatol. 2022 Dec;87(6):1440-1442. doi: 10.1016/j.jaad.2022.07.047. Epub 2022 Aug 4.
4
Cross-Study Comparisons of JAK2 Inhibitors in Myelofibrosis: Risks and Recommendations.骨髓纤维化中 JAK2 抑制剂的跨研究比较：风险和建议。
Clin Lymphoma Myeloma Leuk. 2023 Oct;23(10):714-718. doi: 10.1016/j.clml.2023.06.004. Epub 2023 Jun 9.
5
Weight gain secondary to the use of Janus kinase inhibitors.使用Janus激酶抑制剂继发的体重增加。
Arch Dermatol Res. 2023 Dec;315(10):2773-2774. doi: 10.1007/s00403-023-02710-6. Epub 2023 Aug 23.
6
Emerging protein kinase inhibitors for the treatment of rheumatoid arthritis.新兴的蛋白激酶抑制剂治疗类风湿关节炎。
Expert Opin Emerg Drugs. 2021 Sep;26(3):303-321. doi: 10.1080/14728214.2021.1964472. Epub 2021 Aug 16.
7
Filgotinib for moderately to severely active ulcerative colitis.非戈替尼治疗中重度活动性溃疡性结肠炎。
Expert Rev Gastroenterol Hepatol. 2022 Oct;16(10):927-940. doi: 10.1080/17474124.2022.2138857. Epub 2022 Nov 14.
8
Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.在对肿瘤坏死因子抑制剂反应不足的活动性类风湿关节炎患者中，非肿瘤坏死因子生物制剂和 Janus 激酶抑制剂的比较有效性和安全性：一项随机对照试验的贝叶斯网络荟萃分析
J Clin Pharm Ther. 2021 Aug;46(4):984-992. doi: 10.1111/jcpt.13380. Epub 2021 Feb 18.
9
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).欧洲临床微生物学和传染病学会（ESCMID）感染宿主研究组（ESGICH）关于靶向和生物治疗安全性的共识文件：传染病学视角（细胞内信号通路：酪氨酸激酶和 mTOR 抑制剂）。
Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S53-S70. doi: 10.1016/j.cmi.2018.02.009. Epub 2018 Feb 16.
10
The Emerging Safety Profile of JAK Inhibitors in Rheumatic Diseases.风湿性疾病中 JAK 抑制剂的新兴安全性特征。
BioDrugs. 2023 Sep;37(5):625-635. doi: 10.1007/s40259-023-00612-7. Epub 2023 Jun 23.

引用本文的文献

1
Down Syndrome and Autoimmune Disease.唐氏综合征与自身免疫性疾病。
Clin Rev Allergy Immunol. 2024 Jun;66(3):261-273. doi: 10.1007/s12016-024-08996-2. Epub 2024 Jun 24.

本文引用的文献

1
Autoimmunity in Down's syndrome via cytokines, CD4 T cells and CD11c B cells.唐氏综合征的自身免疫：细胞因子、CD4 T 细胞和 CD11c B 细胞。
Nature. 2023 Mar;615(7951):305-314. doi: 10.1038/s41586-023-05736-y. Epub 2023 Feb 22.
2
Down syndrome and biological treatments in dermatology: Efficacy and safety in our real-life experience and review of literature.唐氏综合征与皮肤科的生物治疗：我们真实世界的经验与文献复习中的疗效和安全性。
Australas J Dermatol. 2023 May;64(2):285-288. doi: 10.1111/ajd.14006. Epub 2023 Feb 13.
3
Treatment of Down Syndrome-Associated Arthritis with JAK Inhibition.
用JAK抑制疗法治疗唐氏综合征相关关节炎。
Case Rep Rheumatol. 2022 Jul 16;2022:4889102. doi: 10.1155/2022/4889102. eCollection 2022.
4
Hidradenitis suppurativa and Down syndrome in a single-centre sample: A cross-sectional study.化脓性汗腺炎合并唐氏综合征的单中心样本：一项横断面研究。
Australas J Dermatol. 2022 Aug;63(3):e231-e237. doi: 10.1111/ajd.13872. Epub 2022 May 14.
5
Down Syndrome-Associated Arthritis (DA): Diagnostic and Management Challenges.唐氏综合征相关关节炎（DA）：诊断与管理挑战
Pediatric Health Med Ther. 2022 Mar 14;13:53-62. doi: 10.2147/PHMT.S282646. eCollection 2022.
6
The Clinical Spectrum of Inflammatory Bowel Disease Associated With Specific Genetic Syndromes: Two Novel Pediatric Cases and a Systematic Review.与特定遗传综合征相关的炎症性肠病的临床谱：两例新的儿科病例及系统评价
Front Pediatr. 2021 Oct 26;9:742830. doi: 10.3389/fped.2021.742830. eCollection 2021.
7
Adalimumab Therapy in a Patient with Psoriasis, Down Syndrome, and Concomitant Hepatitis B Virus Infection.阿达木单抗治疗一名患有银屑病、唐氏综合征并伴有乙型肝炎病毒感染的患者。
Biologics. 2021 Sep 1;15:375-378. doi: 10.2147/BTT.S317888. eCollection 2021.
8
Down Syndrome-Associated Arthritis Cohort in the New Childhood Arthritis and Rheumatology Research Alliance Registry: Clinical Characteristics, Treatment, and Outcomes.新儿童关节炎与风湿病研究联盟注册中心的唐氏综合征相关关节炎队列：临床特征、治疗及结局
Arthritis Care Res (Hoboken). 2021 Dec;73(12):1739-1745. doi: 10.1002/acr.24418.
9
Pneumonia and respiratory infections in Down syndrome: A scoping review of the literature.唐氏综合征相关肺炎和呼吸道感染：文献综述
Am J Med Genet A. 2021 Jan;185(1):286-299. doi: 10.1002/ajmg.a.61924. Epub 2020 Oct 19.
10
Hidradenitis suppurativa and Down syndrome: A systematic review and meta-analysis.化脓性汗腺炎与唐氏综合征：一项系统评价与荟萃分析。
Pediatr Dermatol. 2020 Nov;37(6):1044-1050. doi: 10.1111/pde.14326. Epub 2020 Sep 6.